| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Multiple targets including tight junction proteins, TNF, HSP, and IL receptors (metabolic and inflammatory pathways).
|
|---|---|
| ln Vitro |
Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. It suppresses fat accumulation and ameliorates associated metabolic disorders.
|
| ln Vivo |
In vivo, xylobiose supplementation significantly reduces body weight, fat and liver weights, fasting blood glucose, and blood lipid levels in diet-induced obese rats, demonstrating its anti-obesity and metabolic benefits.
|
| Enzyme Assay |
Xylobiose's effects on metabolic and inflammatory pathways are assessed in cell-free biochemical assays. These may include enzyme activity assays for digestive enzymes, antioxidant capacity measurements, and binding studies to assess interactions with tight junction proteins or inflammatory mediators.
|
| Cell Assay |
Xylobiose is evaluated in cell-based assays using intestinal epithelial cells or immune cells to assess its effects on barrier integrity, inflammatory cytokine production, and oxidative stress markers. Cellular models of metabolic dysfunction may also be employed.
|
| Animal Protocol |
In vivo studies are conducted in diet-induced obese rat models to assess the anti-obesity effects of xylobiose. Animals are fed a high-fat diet supplemented with xylobiose, and parameters including body weight, fat accumulation, blood glucose, and blood lipid levels are measured.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for xylobiose. As a natural disaccharide, it is expected to be metabolized by gut microbiota and have limited systemic absorption, but specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for xylobiose. As a natural product derived from hemicelluloses, it is generally considered safe for consumption, but specific toxicity studies have not been published.
|
| References | |
| Additional Infomation |
Xylobiose is a glycosylxylose, specifically D-xylanose, with a β-D-xylanose residue linked at position 4 via a glycosidic bond. It is a bacterial metabolite. Xylobiose has been reported to be present in Streptomyces ipomoeae, Streptomyces rameus, and Chlamydomonas reinhardtii, and relevant data are available for reference.
Xylobiose is a disaccharide with a molecular formula of C10H18O9 and a molecular weight of 282.2. It is a natural product found in hemicelluloses and has therapeutic potential for treating obesity, type 2 diabetes, and metabolic syndrome through suppression of fat deposition, reduction of blood sugar and blood lipids, and amelioration of oxidative stress and inflammation. It has not been approved as a drug. |
| Molecular Formula |
C10H18O9
|
|---|---|
| Molecular Weight |
282.2445
|
| Exact Mass |
282.095
|
| CAS # |
6860-47-5
|
| PubChem CID |
439538
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
604.0±55.0 °C at 760 mmHg
|
| Flash Point |
235.1±25.0 °C
|
| Vapour Pressure |
0.0±3.9 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
-0.88
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2COC([C@@H]([C@H]2O)O)O)O)O)O
|
| InChi Key |
LGQKSQQRKHFMLI-WSNPFVOISA-N
|
| InChi Code |
InChI=1S/C10H18O9/c11-3-1-18-10(8(15)5(3)12)19-4-2-17-9(16)7(14)6(4)13/h3-16H,1-2H2/t3-,4-,5+,6+,7-,8-,9?,10+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-[(3R,4R,5R)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~885.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (354.31 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5431 mL | 17.7154 mL | 35.4308 mL | |
| 5 mM | 0.7086 mL | 3.5431 mL | 7.0862 mL | |
| 10 mM | 0.3543 mL | 1.7715 mL | 3.5431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
